Introduction
============

Patients with chronic renal failure are at risk of acquiring microorganisms and developing infections. The most common etiologic agents are bacteria and viruses, such as the Torque teno virus (TTV). TTV was discovered in 1997 in the bloodstream of Japanese patients with post-transfusion hepatitis, and its name is derived from the initials of the first patient diagnosed. The initials of the name can also indicate a transfusion-transmitted virus ( [@B20] ; [@B21] ; [@B04] ), although transfusions are not the most frequent means of transmission ( [@B31] ). Subsequently, this virus was named Torque Teno, keeping the initials TTV ( [@B06] ).

Studies indicate that the estimated frequency of the virus can vary with the genomic region tested, as well as with the geographic location studied ( [@B04] ). The modes of transmission are incompletely understood and are widely discussed in the literature. Parenteral transmission is an important propagation route ( [@B20] ), but the virus can also be transmitted by blood transfusion ( [@B22] ) and by blood derivatives ( [@B03] ). Other routes have been identified, including sexual ( [@B16] ; [@B28] ), vertical ( [@B14] ; [@B02] ), and fecal-oral ( [@B17] ; [@B13] ).

TTV is present worldwide ( [@B26] ; [@B01] ), and is organized in five large phylogenetic groups ( [@B23] ). This high genetic diversity implies that some genotypes may have a pathogenic potential ( [@B28] ), but their clinical significance is unknown ( [@B04] ). The epidemiology of TTV is little studied, resulting in limited knowledge about the pathogenesis of this viral particle.

A patient's history of multiple blood transfusions is associated with the acquisition of TTV. Lowered immunity can increase the probability of developing a viremia ( [@B32] ; [@B27] ). Although the effects of these factors require clarification, the diagnosis of TTV continues to be difficult because the antibody corresponding to the infection cannot be detected ( [@B08] ).

Considering the risk of a TTV infection in patients undergoing renal therapy, and also the need for monitoring to aid in developing measures to control or prevent the transmission of this infectious agent, this study had the objectives of identifying the presence of TTV and its genomic groups in blood samples from patients undergoing dialysis and renal transplant treatment, and evaluating the association between TTV frequency and several variables including gender, age, time in dialysis, time since transplant, blood transfusions, and the concomitant presence of the hepatitis B virus.

Materials and Methods
=====================

A quantitative study with a descriptive exploratory approach was carried out in the dialysis unit of a medium-sized hospital in the city of Maringá, Paraná. During the period of data collection, from January to June 2011, the unit registered 153 patients in dialysis and 60 renal-transplant patients. The patients who underwent renal transplants formed a distinct group from the dialysis patients, since they were not on dialysis. These individuals were recruited during routine clinical consultation. The study sample was composed of 118 dialysis and 50 renal-transplant patients, aged 18 years or more. Individuals who showed difficulty in understanding or clinical instability during the data collection were excluded, as were patients who declined to participate in the study.

We analyzed the frequency of TTV with respect to its association with gender, age, time in dialysis, time since transplant, number of blood transfusions and the presence of hepatitis B. For this last variable, we used information from medical records.

Peripheral blood samples (10 mL) was collected by venipuncture, in sterilized vacuum tubes with an anticoagulant. For DNA extraction the PureLink® genomic DNA (Invitrogen) kit was used, following the manufacturer's recommendations. The genomic DNA was detected by electrophoresis at 100 V for 20 min, using 1.5% agarose gel, staining with ethidium bromide and observation in ultraviolet light.

The viremia in the peripheral blood was identified through the nested PCR technique, using the primers RD037 (5′-GCAGCAGCATATGGATATGT-3′), RD038 (5′-TGACTGTGCTAAGGCCTCTA-3′), RD051 (5′-CATACACATGAATGCCAGGC-3′) and RD052 (5′-GTACTTCTTGCTGGTGAAAT-3′) ( [@B20] ). The final product indicating the presence of TTV was an amplified fragment of 197 bp. Both amplification reactions were carried out under the same conditions, using a final volume of 25 μL and the following reagents: 0.75 μL MgCl ~2~ (50 mM); 2.0 μL of dNTP (1.25 mM); 1.0 μL of sense primer (2.5 μM); 1.0 μL of anti-sense primer (2.5 μM); 12.75 μL of sterile Milli-Q H ~2~ O; 2.5 μL of taq polymerase (1.25 U/reaction); and 2.5 μL of genomic DNA sample and/or PCR 1 product (0.1 μg/μL).

The first and second rounds of amplification used an initial denaturing temperature at 94 °C for 10 min, followed by 35 cycles of 30 s at 94 °C to denature the double strand of DNA, 30 s at 53 °C for annealing, and 45 s at 72 °C for extension, with a final extension of 10 min at 72 °C. The amplified product was observed by electrophoresis in 2% agarose gel at 90 V for 35 min, and staining with ethidium bromide.

The genomic groups were detected using genomic DNA with 3 universal primers as proposed by [@B11] . The nested PCR was carried out with the amplified product, using 5 primers for the identification of genomic groups 1 to 5 ( [@B11] ). Summarizing, the amplification reaction of the first round was carried out with a final volume of 25 μL, composed of 2.5 μL of DNA, 0.2 mM dNTP, 3 mM MgCl ~2~ , 0.2 μM of each sense and anti-sense primer, and 0.75 U of platinum TaqDNA polymerase. After DNA initial denaturing for 1 min and 30 s at 94 °C, the amplification was carried out in 35 cycles at 94 °C for 30 s, 59 °C for 30 s and 72 °C for 3 min 30 s, followed by final elongation for 10 min at 72 °C. The second round of PCR was carried out with 1 μL of the product of the first PCR and 0.5 U of TaqDNA polymerase. The initial DNA denaturing step was 3 min at 94 °C, followed by amplification for 30 cycles at 94 °C for 30 s, 59 °C for 30 s and 72 °C for 1 min 15 s, with a final elongation for 7 min at 72 °C. The amplified product was observed in electrophoresis in 2% agarose gel stained with ethidium bromide and revealed in ultraviolet light. This PCR reaction for the determination of genomic groups was carried out with all 118 samples, including those which showed negative results for the presence of viral DNA.

Statistical analysis
--------------------

The data were recorded in an Excel® spreadsheet. The software Statistica 7.1 was used to obtain the descriptive analysis. In the comparative analyses, Student's t-test and Fischer's exact test were used, with a confidence interval of 95% (p \< 0.05).

Ethical aspects
---------------

This study was conducted with the permission of the Research Ethics Committee of the State University of Maringá, report no. 562/2010, and abided by all ethical principles established by Resolution 196, dated October 10, 1996, of the National Health Council. All individuals signed the free and informed consent form.

Results
=======

The dialysis patients were mostly males (66/118; 55%) with a mean age of 53.8 years (SD, standard deviation 16.0). The mean time in dialysis was 41.8 months (SD 44.7 months). Hepatitis B was present in only 4 dialysis patients (3%); 71 chronic renal patients (60%) had received a blood transfusion.

The group of dialysis patients showed a TTV-positivity rate of 17% (21/118) when the method for detection of viremia proposed by [@B20] was used. In the second reaction, carried out as proposed by [@B11] , the rates of viremia detection increased from 17% (21/118) to 36% (43/118).

No statistically significant association was observed between the TTV frequency (p \> 0.05) and the patients' gender (p = 0.33), age (p = 0.44), time in dialysis (p = 0.66), hepatitis B virus (p = 0.62), or previous blood transfusions (p = 0.55).

Among the dialysis patients, genogroup 5 predominated (48%), followed by genogroup 4 (37%). No patient with genogroup 2 was found in this population. Nearly half (46%) of the patients had only one of the circulating genogroups. No individual possessed four or five genogroups.

There was no statistically significant association (p \> 0.05) between the genogroups identified and the gender, age of the patient, time in dialysis, presence of hepatitis B virus, or blood transfusion. Exceptionally, genogroup 4 showed a significant association with the patients' age and the dialysis time (p \< 0.05). In other words, genogroup 4 was most frequent among patients with a mean age of 64.5 and a mean dialysis period of 19.9 months.

Among the 50 renal-transplant patients, males predominated (32/50; 64%), with a mean age of 44.0 years (SD 12.5). The mean post-transplant period was 99.4 months (SD 49.9 months).

The frequency of TTV in the renal transplant group was 10% (5/50) based on the presence of viral DNA. Use of the nested PCR technique for genogrouping, including all samples, resulted in a frequency of 54%. Also, no significant association was found (p \> 0.05) between positivity for TTV and the patients' gender (p = 0.38), age (p = 0.40) or post-transplant period (p = 0.42).

Analyzing the frequency of each genogroup with respect to gender, age and post-transplant period yielded a significant association only for genogroup 3, with respect to the mean time elapsed since the transplant (p \< 0.05). Genogroup 3 was most frequent among patients with a mean post-transplant period of 46.2 months.

Among renal-transplant patients, genogroup 5 was most prevalent (66%), followed by genogroup 4 (48%), and last by genogroup 2 (7%). For the majority (51%) of patients, only one genogroup was identified. Several patients showed the presence of several genogroups, but none showed the presence of all 5.

Discussion
==========

The PCR technique was used in this study to determine the frequency of entrainment of TTV DNA in samples obtained from the peripheral blood of patients on dialysis and recipients of renal transplants. The choice of primers used in the PCR reaction, to identify the presence of TTV, can strongly affect the level of detection of this microorganism in biological fluids, because certain segments of the viral DNA are less sensitive to the PCR technique ( [@B11] ; [@B31] ). Some investigators have also noted that the high rate of genetic mutation could make the PCR technique less sensitive for identifying this virus ( [@B04] ).

The population of this study is similar to others in different parts of the world, and the results for frequency also vary within a wide range, possibly as a function of different methods used. Also, studies with nucleotide sequences from several samples revealed the existence of mutations in several animal species, creating the need for the virus to adapt to the new host ( [@B05] ; [@B12] ). The use of more than one method, either for TTV identification or for genogrouping, proved to be essential because this is a highly mutable microorganism.

The TTV-positive prevalence of 36% observed among dialysis patients in this study is comparable to findings elsewhere of incidences from 9.3% ( [@B15] ) to 60.9 ( [@B09] ). We are aware of no other study of TTV occurrence among dialysis patients in Brazil. The transplant patients showed a higher prevalence of TTV (54%) than the dialysis patients. This higher frequency could be explained by the immunosuppressive therapy that kidney-transplant patients receive ( [@B07] ). In Brazil, a similar TTV prevalence of 53.8% was found in renal-transplant patients in Campinas ( [@B32] ). However, few studies have investigated the prevalence of TTV in this group.

Research conducted in Italy showed a significant increase in TTV frequency after a liver transplantation procedure ( [@B07] ). This important information highlights the need for further studies to elucidate the possible association with the use of immunosuppressive drugs in recipients of renal transplants.

No significant association was found between TTV positivity and any of the epidemiological variables examined in this study (gender, time in dialysis, blood transfusions and the presence of hepatitis B), for either the dialysis or the renal-transplant patients. Other studies ( [@B32] ; [@B29] ; [@B18] ) have also found a lack of association with blood transfusions or with the presence of the hepatitis B virus. Although the parenteral route is considered the main means of transmission ( [@B09] ), these data suggest that other routes of viral propagation exist. The association between the presence of TTV and the possible etiology of hepatic diseases, a highly controversial subject, needs to be investigated before any causal relationship can be established ( [@B09] ; [@B31] ; [@B25] ).

Genogroup 5 predominated among both the dialysis and transplant patients, and is the largest TTV genogroup circulating in the general Brazilian population (Costa, 2009). Genogroup 2 showed the lowest incidence and was found only among the renal-transplant patients; it is the least common group in Brazil ( [@B11] ). The high frequency of genogroup 4 in both population samples (dialysis: 37%; kidney transplant: 48%) is notable. This finding contrasts with a study conducted in Rio de Janeiro with three different groups of patients (blood donors, patients with hepatitis B and HIV patients), where genogroup 4 was detected in only 17% of the subjects ( [@B11] ). Also in the most recent survey conducted in five Brazilian states (Bahia, Espírito Santo, Minas Gerais, Rio de Janeiro and Rio Grande do Sul), genogroup 4 was present in only 21.5% of all samples analyzed ( [@B24] ). Thus, further studies are needed, including a control group, to determine the general prevalence of each of the genogroups in Brazil.

In both patient populations, the majority of individuals showed only one genogroup, in agreement with other studies conducted in Brazil ( [@B24] ; Vasconcelos *et al.* , 2011). The identification of a single genogroup in most individuals may be favorable for the host's immune system, since the presence of several different genotypes could evade immune surveillance. Viruses that produce long-lasting infections may have coexisted with primates for millions of years, and their DNA shows a wide diversity of genetic variations ( [@B04] ). Over the long run, the continuous TVV viremia could lead the immune system to adapt to the established viral infection ( [@B10] ). It was expected that a greater diversity of genogroups and also the presence of larger numbers of genogroups in the same patient would be found among renal-transplant patients, because of the immunosuppressive therapy that they receive.

The significant association of genogroup 3 with the mean age and mean time in dialysis, as well as the significant association of genogroup 4 with the mean post-transplant period deserve emphasis. The literature contains many studies on frequencies of genogroups, but no study has addressed the cause of this association. Possibly, stratification in younger age groups could clarify this association. There is also a need for more studies of the association of genogroups with epidemiological variables.

A high frequency of viremia was observed in both groups evaluated, in agreement with literature data. There was no statistically significant association between the TTV frequency and the variables gender, age, duration of treatment, blood transfusions or the presence of hepatitis B, in both groups. Further studies will be needed to clarify the significant association observed between genogroup 3 and the mean age and mean time in dialysis, as well as the significant association of genogroup 4 with the mean post-transplant period. The estimated frequency of viremia increased when a second method was used to determine the presence of the virus. Genogroup 5 was the most prevalent, and genogroup 2 occurred least frequently, in agreement with previous findings. In some patients, several genogroups were found. The results point to the need to determine the main routes of transmission of this agent, to aid in implementing barriers to its spread ( [@B19] ). Aspects such as the virus' biology and pathogenic capacity, and the clinical significance of TTV among dialysis and renal-transplant patients require further clarification.
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